Number of the records: 1  

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat

  1. 1.
    SYSNO ASEP0370143
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleHIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
    Author(s) Fun, A. (NL)
    Maarseveen van, N. M. (NL)
    Pokorná, Jana (UOCHB-X) RID
    Maas, R. E. (NL)
    Schipper, P. J. (NL)
    Konvalinka, Jan (UOCHB-X) RID, ORCID
    Nijhuis, M. (NL)
    Number of authors7
    Source TitleRetrovirology. - : BioMed Central
    Roč. 8, č. 70 (2011), s. 1-12
    Number of pages12 s.
    Languageeng - English
    CountryGB - United Kingdom
    Keywordsimmunodeficiency-virus type-1 ; gag spacer peptide-1 ; replication capacity ; compensatory mutations ; cleavage sites
    Subject RIVCE - Biochemistry
    CEZAV0Z40550506 - UOCHB-X (2005-2011)
    UT WOS000295599200001
    DOI10.1186/1742-4690-8-70
    AnnotationMaturation inhibitors are an experimental class of antiretrovirals that inhibit Human Immunodeficiency Virus (HIV) particle maturation, the structural rearrangement required to form infectious virus particles. This rearrangement is triggered by the ordered cleavage of the precursor Gag polyproteins into their functional counterparts by the viral enzyme protease. In contrast to protease inhibitors, maturation inhibitors impede particle maturation by targeting the substrate of protease (Gag) instead of the protease enzyme itself. Direct cross-resistance between protease and maturation inhibitors may seem unlikely, but the co-evolution of protease and its substrate, Gag, during protease inhibitor therapy, could potentially affect future maturation inhibitor therapy. Previous studies showed that there might also be an effect of protease inhibitor resistance mutations on the development of maturation inhibitor resistance, but the exact mechanism remains unclear. We used wild-type and protease inhibitor resistant viruses to determine the impact of protease inhibitor resistance mutations on the development of maturation inhibitor resistance.
    WorkplaceInstitute of Organic Chemistry and Biochemistry
    Contactasep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Viktorie Chládková, Tel.: 232 002 434
    Year of Publishing2012
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.